Previous study also revealed that Met in combination with first-generation TKI effectively increased the sensitivity of TKI-resistant lung cancer cells and blocked tumor growth in xenografts, associated with decreased IL-6 secretion, reversal of EMT and dampened IL-6/STAT3 signaling [22]. The gene discussed is IL6; the disease is lung carcinoma.